Table_1_Nicotinamide N-Methyltransferase Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric Cancer.DOC

Gastric cancer (GC) is the third most common cause of cancer-related death in the word. Immunotherapy is a promising treatment of cancer. However, it is unclear which GC subpopulation would benefit most from immunotherapy and it is necessary to develop effective biomarkers for predicting immunotherapy response. Nicotinamide N-methyltransferase (NNMT) is a metabolic regulator of cancer-associated fibroblast (CAF) differentiation and cancer progression. In this study, we explored the correlations of NNMT to tumor-infiltrating immune cells (TIICs) and immune marker sets in The Cancer Genome Atlas Stomach Adenocarcinoma STAD (TCGA-STAD). Subsequently, we screened the NNMT correlated genes and performed the enrichment analysis of these genes. We eventually predicted the 19 most potential small-molecule drugs using the connectivity map (CMap) and Comparative Toxicogenomics Database (CTD). Also, nadolol, tranexamic acid, felbinac and dapsone were considered the four most promising drugs for GC. In summary, NNMT can be used as a prognostic biomarker that reflect immune infiltration level and a novel therapeutic target in GC.

胃癌（GC）是全球癌症相关死亡原因中的第三大杀手。免疫治疗作为一种极具潜力的癌症治疗方法，然而，目前尚不清楚哪种GC亚群将最大程度地受益于免疫治疗，因此开发有效的生物标志物以预测免疫治疗反应变得尤为必要。烟酰胺N-甲基转移酶（NNMT）是调控癌症相关成纤维细胞（CAF）分化和癌症进展的代谢调节因子。在本研究中，我们探讨了NNMT与肿瘤浸润免疫细胞（TIICs）及免疫标记集在癌症基因组图谱胃腺癌（TCGA-STAD）中的相关性。随后，我们对NNMT相关基因进行了筛选，并对这些基因进行了富集分析。最终，我们利用连接图（CMap）和比较毒理学数据库（CTD）预测了19种最具潜力的小分子药物。此外，纳多洛尔、氨甲环酸、芬必得和阿的平被认定为四种最有希望的GC治疗药物。总之，NNMT可作为反映免疫浸润水平的预后生物标志物，并在胃癌中作为一个新颖的治疗靶点。